Lopinavir/ritonavir pharmacokinetic profile: Impact of sex and other covariates following a change from twice-daily to once-daily therapy

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 970-977

  Ofotokun, Ighovwerha ^a   Chuck, Susan K ^b   Binongo, Jose N ^c   Palau, Mauricio ^a   Lennox, Jeffrey L ^a   Acosta, Edward P ^d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ABBOTT LABORATORIES   (United States)

^c EMORY UNIVERSITY   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Gender or sex related differences; Lopinavir pharmacokinetics

Indexed keywords

LOPINAVIR PLUS RITONAVIR; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DETERMINATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; SEX DIFFERENCE; STATISTICAL ANALYSIS; STEADY STATE;

ADENINE; ADULT; AREA UNDER CURVE; CAPSULES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SEX FACTORS;

EID: 34447619487     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007302564     Document Type: Article

References (28)

1. Fletcher CV, Acosta EP, Strykowski JM Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health. 1994 ; 15: 619-629.
2. Csajka C., Marzolini C., Fattinger K., et al. Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother. 2004 ; 48: 3226-3232.
3. Hirt D., Urien S., Jullien V., et al. Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children. Antimicrob Agents Chemother. 2006 ; 50: 910-916.
4. Haas DW, Smeaton LM, Shafer RW, et al. Pharmacogenetics of long-term responses to antiretroviral REGIMENS containing efavirenz and/or nelfinavir: an Adult AIDS Clinical Trials Group Study. J Infect Dis. 2005 ; 192: 1931-1942.
5. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents (pp 78-88). May 4, 2006. Available at: http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
6. Fletcher CV, Jiang H., Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004 ; 189: 1176-1184.
7. Pai MP, Schriever CA, Diaz-Linares M., et al. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004 ; 24: 592-599.
8. Zhou XJ, Sheiner LB, D'Aquila RT, et al. Population pharmacokinetics of nevirapine, zidovudine and didanosine I human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother. 1999 ; 43: 121-128.
9. Burger DM, la Porte Cjl, van der Ende, et al. Gender related differences in efavirenz pharmacokinetics. Abstract 3.6. In: Program and Abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy. March 27-29, 2003 ; Cannes, France.
10. Anderson PL, Kakuda TN, Kawle S., Fletcher CV Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS. 2003, 17: 2159-2168.
11. Eron JJ, Feinberg J., Kessler HA, et al. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J Infect Dis. 2004: 189: 265-272.
12. Gleiter CH, Gundert-Remy U. Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet. 1996 ; 21: 123-128.
13. Bertz R., Lam W., Hsu A., et al. Effects of gender, race, age and weight on the pharmacokinetics of lopinavir after single-dose Kaletra™. Abstract 3.11. In: Program and Abstracts of the 2nd International Workshop on Clinical Pharmacology of HIV Therapy. April 2-4, 2001 ; Noordwijk, the Netherlands.
14. Poirier J., Zouai O., Meynard J., et al. Lack of effect of gender, age, weight and body mass index on trough lopinavir plasma concentrations in HIV-infected patients. Abstract 49. In: Program and Abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy. March 27-29, 2003 ; Cannes, France.
15. Cernohous P., Bernstein B., Moseley J., et al. Safety and efficacy of lopinavir/ritonavir in women in a phase iii study of antiretroviralnaïve subjects. Abstract WePeB5972. In: Program and Abstracts of the XIV International AIDS Conference. July 7-12, 2002 ; Barcelona, Spain.
16. Walmsley S., Bernstein B., King M., et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002 ; 346: 2039-2046.
17. Burger DM, Muller RJ, van de Leur MR, la Porte Cjl. Lopinavir plasma levels are significantly higher in females. Abstract 6.5. In: Program and Abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy. April 11-13, 2002 ; Washington, DC.
18. Flaherty JF, Kearney BP, Wolf JJ, et al. A multiple-dose, randomized, crossover drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. Abstract 336. In: Program and Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment July 8-11, 2001 ; Buenos Aires, Argentina.
19. Kearney BP, Mittan A., Sayre J., et al. Pharmacokinetic drug interaction and long term safety profile of tenofovir DF and lopinavir/ritonavir. Abstract A-1617. In: Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 14-17, 2003 ; Chicago, Ill.
20. Kearney B., Mathias A., Mittan A., et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006 ; 43: 278-283.
21. Taburet A., Piketty C., Chazallon C., et al. Interactions between atazanavir-ritonavir and tenofovir in Heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 2004 ; 48: 2091-2096.
22. Fletcher CV, Acosta EP, Cheng H., et al. Competing drug-drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. AIDS. 2000 ; 14: 2495-2501.
23. Bertz R., Renz C., Foit C., et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food. Abstract 3.1. In: Proceedings of the Second International Workshop on Clinical Pharmacology of HIV Therapy. April 2-4, 2001 ; Noordwijk, the Netherlands.
24. Kaletra. Kaletra (US prescribing information). North Chicago, Ill: Abbott Laboratories ; 2005.
25. Johnson MA, Gathe JC Jr, Podzamczer D., et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006 ; 43: 153-160.
26. Chiu Y-L., Foit C., Gathe J., et al. Multiple-dose pharmacokinetics and initial antiviral effect of once daily lopinavir/ritonavir (LPV/r) in combination with tenofovir (TDF) and emtricitabine (FTC) in HIV-infected antiretroviral-naive subjects (study 418). Poster presented at: the Second International AIDS Society Conference on HIV Pathogenesis and Treatment ; 2003 ; Paris, France.
27. Johnson M., DeJesus E., Grinsztejn B., et al. Long-term efficacy and durability of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in HIV-infected patients with multiple virologic failures: 96-Week results from a randomized, open-label trial, BMS AI424045. Abstract #PL14.4. Paper presented at: the 7th International Congress on Drug Therapy in HIV Infection ; November 14-18, 2004 ; Glasgow, UK.
28. van Gelder J., Deferme S., Naesens L., et al. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metab Dispos. 2002 ; 30: 924-930.